Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders. He is currently the global lead investigator for lenalidomide for patients with relapsed/refractory mantle cell lymphoma for whom bortezomib had failed. Dr. Goy is also the co-investigator in a number of clinical trials in lymphomas, including the very promising kinase inhibitors targeting the BCR pathway, especially ibrutinib, which showed dramatic activity in a number of B-cell lymphomas, especially mantle cell lymphoma.

Dr. Goy has trained at the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center, Assistance Publique in Paris (the largest university hospital system in Europe), and The Pasteur Institute, also in Paris.

Kim Formica, Revenue/Billing Director

Kim Formica is Director of Revenue Cycle and Billing Compliance at Regional Cancer Care Associates. Formica has four years of experience in oncology billing and collections, is a certified professional coder (CPC), and has more 20 years of prior healthcare billing and operations experience. Prior to joining RCCA, she was Director of Billing/Collections for Medical Resources, Inc., a freestanding imaging company that operated in nine states. Her oversight included reporting from five remote regional billing centers. Her current responsibilities include assuring billing compliance and maintaining oversight of RCCA daily reconciliations.

Terrill Jordan, President & CEO

Terrill Jordan is President and Chief Executive Officer at Regional Cancer Care Associates, positions he began serving on January 1, 2016. Under his leadership, RCCA is driving to become a national leader in high-quality, value-based community oncology care. Prior to his current position, Jordan served as Vice President and Chief Legal Officer focusing principally on healthcare legal oversight, providing strategic advice, commercial negotiations, and mergers and acquisitions as part of the senior management team. In this role, Jordan was also responsible for advising the Board of Managers on governance and compliance issues. Jordan has more than 20 years’ experience in business and commercial matters in a range of industries, including healthcare, technology, power and energy, transportation, infrastructure, heavy equipment, and real estate. Jordan graduated from New York University School of Law with an LL.M. and received J.D. and B.S. degrees from University of Florida. Jordan is also a Florida certified public accountant.

Alizah Diamond, Corporate Counsel

Alizah Diamond is Corporate Counsel–Commercial Contracts and Employment at Regional Cancer Care Associates (RCCA). She is responsible for oversight of RCCA’s legal matters, including commercial contracts and transactions, healthcare regulatory compliance, mergers and acquisitions, employment/HR matters, and other areas that impact RCCA’s clinical office and commercial business lines.

Prior to joining RCCA, Alizah was an attorney at Schnader Harrison Segal & Lewis LLP and Hodes Ulman Pessin & Katz, P.A., representing companies in commercial and employment transactions and litigation in a wide range of industries. She received her J.D. from Georgetown University Law Center and her B.A. from the Johns Hopkins University. Alizah was named a New York City Super Lawyers “Rising Star” in 2014 and 2015. She is licensed to practice law in Maryland, New Jersey (In-House) and New York.

Michael Ruiz de Somocurcio, VP–Payer & Provider Collaboration

Michael Ruiz de Somocurcio is Vice President–Payer and Provider Collaboration for Regional Cancer Care Associates. His responsibilities include contracting, data analytics, developing value-based arrangements with health plans and CMS, and supporting growth strategies in new and existing markets. Prior to joining RCCA, he spent more than 15 years on the health plan side working for national, regional and start-up health plans. Most recently, he held COO and VP roles at Amerigroup, Oscar Insurance and AmeriHealth NJ, where he led network contracting, strategic initiatives and medical cost containment. Throughout his career, Ruiz de Somocurcio has developed innovative partnerships to transform the delivery of care through network design and value-based outcomes between health plans, hospitals and physician groups. He holds a BS in Business Administration from the College of NJ and an MBA from Rutgers University. He speaks locally and nationally on a broad range of healthcare topics but is most passionate about improving the healthcare delivery system.

Andre Goy, MD, Chief Science Officer

As Chief Science Officer and Director of Research and Innovation, Dr. Andre Goy is responsible for developing strategies that will bring research and clinical trials to all RCCA locations. Under Dr. Goy’s leadership, patients in local communities throughout New Jersey will be able to access cutting-edge clinical trials focused on novel therapies and biomarker-driven research.

Dr. Goy also continues to serve as Chairman and Executive Director at John Theurer Cancer Center at Hackensack University Medical Center, one of the 50 best hospitals for cancer and RCCA’s Hackensack location, where he has been instrumental in elevating the research program to become one of the largest, most active in the nation. The research program now includes more than 200 clinical trials across 14 cancer divisions with Phase I, II and III protocols. Dr. Goy also spearheaded the development of the Tissue Bank, and leads New Jersey’s largest program for lymphoma.

An internationally renowned clinician and researcher, Dr. Goy is widely known for his work showing the first evidence of activity of bortezomib (Velcade) in mantle cell lymphoma, which led to the FDA’s approval of bortezomib for relapsed/refractory mantle cell lymphoma. He also took part in the original pilot study for rituximab (Rituxan), which has been widely used to treat lymph